WebMerus discovers, develops, and manufactures differentiating therapeutics to treat and cure cancer patients. The company develops products using bispecific antibody engineering … Web10 apr. 2024 · Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. About the company Rewards Revenue is forecast to grow 38.4% per year Risk Analysis Currently unprofitable and not forecast to become profitable over the next 3 years Shareholders have been diluted in …
Battling cancer with bispecific antibodies - Nature
Web7 jan. 2024 · Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ®. Web26 okt. 2024 · Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. continuous division of 72
Merus, Elevation Oncology Advance Drug Candidates Targeting …
Web7 jun. 2024 · CAMBRIDGE, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. WebAllogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering ... Web31 jul. 2024 · Merus initially had broader development plans for its zenocutuzumab as a treatment for patients who are HER2-positive or had HER3-mediated resistance to a HER2 agent. Last year, Merus decided to home in on NRG1 fusion-positive cancers and revised one of the ongoing Phase II trials into the eNRGy trial. continuous division of 33